SRR934951
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 109.42838370565046
- age_years
- 38
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.388
- MYC_TARGETS_V1+0.359
- MITOTIC_SPINDLE+0.356
- NOTCH_SIGNALING+0.348
- WNT_BETA_CATENIN_SIGNALING+0.341
- MYC_TARGETS_V2+0.323
- DNA_REPAIR+0.291
- HEDGEHOG_SIGNALING+0.289
- TGF_BETA_SIGNALING+0.289
- E2F_TARGETS+0.288
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.454
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.451
- INFLAMMATORY_RESPONSE-0.437
- ANGIOGENESIS-0.352
- COAGULATION-0.348
- IL2_STAT5_SIGNALING-0.337
- COMPLEMENT-0.326
- INTERFERON_GAMMA_RESPONSE-0.324
- IL6_JAK_STAT3_SIGNALING-0.321
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.314
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0730F3DB-384B-43E6-A69F-BF3F7C2CCE78 | — | — | 0.946 |
| 2 | 9CC5EB30-A8C2-4FDF-8074-467AA98ED1CA | — | — | 0.941 |
| 3 | EED16435-CBED-4143-B5BA-C5C7C8510C3A | — | — | 0.934 |
| 4 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.927 |
| 5 | CB9E4206-E2F7-49EA-8FB2-E69E5BB3B018 | — | — | 0.925 |
| 6 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.917 |
| 7 | 4F62A177-D1C6-4829-A86E-7CA1D29421FC | — | — | 0.916 |
| 8 | 10FB7E59-9D71-4AB9-8D06-9CFD2304D1BC | — | — | 0.915 |
| 9 | SRR934805 | — | — | 0.912 |
| 10 | E6090BC6-D29D-4401-990A-251930CC6853 | — | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.388 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.359 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.356 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.348 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.341 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.323 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.291 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.289 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.289 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.288 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.215 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.182 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.173 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.165 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.156 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.034 | Idelalisib | — uncovered |